September 9, 2025 Global oncology leader brings decades of experience advancing breakthrough therapies to help guide Vicero’s VVH VINCOBODY pipeline into the clinic CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODIES for solid tumors, today announced the appointment of Han Myint, MD, FACP, as Chief Medical Officer. Dr. Myint will lead the clinical [...]

March 24, 2025 Dr. Sumit Subudhi and Dr. Antoni Ribas bring world-class expertise in immuno-oncology to help guide development of company’s VINCOBODY Platform CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODIES for immune-mediated diseases, today announced the appointment of two distinguished oncologists and immunotherapy experts, Sumit Subudhi, M.D., Ph.D., and Antoni Ribas, M.D., [...]

February 24, 2025 Late-breaker poster presentation at the inaugural AACR IO underscores potential of VCR-036, a novel PD-1/CTLA-4 VHH antibody for treatment of solid tumors Being developed to solve limitations due to toxicity and efficacy that exist in the current immuno-oncology standard of care CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODIES [...]